Investor Presentaiton

TC TCB's Allogeneic Platform Profile BIOPHARM GDTs provide a unique product development platform, which will enable next- generation infectious disease therapies ■ Marked responses seen in AML Primed for other blood cancer treatment ■ No toxicity Established clinical proof-of-safety (high dose) "Off the Shelf" capabilities with frozen/thawed product EFFECTIVE SAFE ECONOMICAL 19 ■ TCB's allogeneic products will cost substantially less than current therapies ■ Can be campaign manufactured

View entire presentation